ZLAB Zai Lab Ltd

$35.73

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/18/2025

About Zai Lab Ltd

Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.

Website: https://www.zailaboratory.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
China
Currency
USD
Fiscal Year End
December
CIK
1704292
Address
4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI, CHINA
Valuation
Market Cap
$3.22B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
3.76
Performance
EPS
$-2.60
Dividend Yield
—
Profit Margin
-64.40%
ROE
-31.40%
Technicals
50D MA
$32.93
200D MA
$26.07
52W High
$39.77
52W Low
$14.48
Fundamentals
Shares Outstanding
110M
Target Price
$54.87
Beta
1.09

ZLAB EPS Estimates vs Actual

● Estimated
● Actual

ZLAB News & Sentiment

Jul 23, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Zai Lab Limited ( ZLAB ) Stock Jumps 6.8%: Will It Continue to Soar?
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Jul 18, 2025 • Benzinga NEUTRAL
Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session - BlackSky Technology ( NYSE:BKSY ) , Greenlane Hldgs ( NASDAQ:GNLN )
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Friday. Shares of Netflix, Inc. NFLX fell in pre-market trading following second-quarter results. Netflix reported second-quarter revenue of $11.08 billion, up 16% year-over-year.
Jun 30, 2025 • Benzinga SOMEWHAT-BULLISH
Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects - Amgen ( NASDAQ:AMGN )
Bemarituzumab plus chemo improved survival in FGFR2b+ advanced gastric cancer patients. Most common side effects included visual issues, anemia, neutropenia, and nausea. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July.
Jun 04, 2025 • Benzinga SOMEWHAT-BULLISH
Guidewire Software Posts Upbeat Q3 Results, Joins Yext, REV Group And Other Big Stocks Moving Higher On Wednesday - Guidewire Software ( NYSE:GWRE ) , Applied Digital ( NASDAQ:APLD )
U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Guidewire Software, Inc. GWRE rose sharply during Wednesday's session after the company reported better-than-expected third-quarter financial results.
Jun 02, 2025 • Benzinga SOMEWHAT-BULLISH
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - NovoCure ( NASDAQ:NVCR ) , Zai Lab ( NASDAQ:ZLAB )
Median overall survival improved to 16.2 months with TTFields vs. 14.2 months for standard treatment. TTFields extended pain-free survival by 6.1 months, reaching a median of 15.2 months. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.
May 15, 2025 • GlobeNewswire NEUTRAL
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around ...
Sentiment Snapshot

Average Sentiment Score:

0.086
50 articles with scored sentiment

Overall Sentiment:

Neutral

ZLAB Reported Earnings

Feb 25, 2025
Dec 31, 2024 (Pre market)
-0.17 Surprise
  • Reported EPS: $-0.80
  • Estimate: $-0.63
  • Whisper: —
  • Surprise %: -26.3%
Nov 12, 2024
Sep 30, 2024 (Pre market)
0.36 Surprise
  • Reported EPS: $-0.42
  • Estimate: $-0.78
  • Whisper: —
  • Surprise %: 46.1%
Aug 06, 2024
Jun 30, 2024 (Post market)
-0.09 Surprise
  • Reported EPS: $-0.80
  • Estimate: $-0.71
  • Whisper: —
  • Surprise %: -12.7%
May 08, 2024
Mar 31, 2024 (Post market)
0.42 Surprise
  • Reported EPS: $-0.50
  • Estimate: $-0.92
  • Whisper: —
  • Surprise %: 45.6%
Feb 27, 2024
Dec 31, 2023 (Post market)
-0.14 Surprise
  • Reported EPS: $-1.00
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -16.3%
Nov 07, 2023
Sep 30, 2023 (Post market)
0.33 Surprise
  • Reported EPS: $-0.71
  • Estimate: $-1.04
  • Whisper: —
  • Surprise %: 31.7%
Aug 07, 2023
Jun 30, 2023 (Post market)
-0.46 Surprise
  • Reported EPS: $-1.25
  • Estimate: $-0.79
  • Whisper: —
  • Surprise %: -58.2%
May 09, 2023
Mar 31, 2023 (Post market)
0.44 Surprise
  • Reported EPS: $-0.51
  • Estimate: $-0.95
  • Whisper: —
  • Surprise %: 46.3%
Mar 01, 2023
Dec 31, 2022 (Post market)
0.46 Surprise
  • Reported EPS: $-0.65
  • Estimate: $-1.11
  • Whisper: —
  • Surprise %: 41.4%

Financials